Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04888936 · ClinicalTrials.gov registry record

Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies

A clinical trial of Noonan Syndrome and Legius Syndrome, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
500
Enrollment target
2
Study locations

NCT04888936 is a study of Noonan Syndrome and Legius Syndrome that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 500 participants, above the 293-participant average among 4 other Noonan Syndrome trials with a reported enrollment target (71% higher). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04888936, a study of Noonan Syndrome and Legius Syndrome, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
500 participants
Enrollment target
2
Study locations

Study Summary

Background: RASopathies are a group of conditions caused by a genetic change. People with a RASopathy may have developmental issues, cognitive disability, poor growth, and birth defects. They may also have an increased risk for developing cancer. Researchers want to learn more. Objective: To learn more about RASopathies, how genes and environmental factors contribute to cancer development in people with RASopathies, and the best way to find these cancers and other conditions early or prevent them. Eligibility: People of any age who have or may have a RASopathy, and their family members. Design: Participants will complete questionnaires about their personal and family medical history. Their medical records will be reviewed. Participants will give blood and urine samples. They will give a saliva or cheek cell sample. Some samples will be used for genetic testing. Participants may have a skin biopsy. Participants may have a physical exam by the RASopathies study team. They may also have exams by additional specialists, such as dentists; urologists; ear, nose, and throat doctors; and neurologists. Participants may have computed tomography of the face and mouth. They may have an ultrasound of the abdomen. They may have a bone density scan. They may have skeletal and/or spine x-rays. They may have magnetic resonance imaging of the brain, low back, chest, and/or heart. They may be photographed. Participants may have other tests, such as sleep, brain and heart electrical activity, speech and swallow, metabolism, hearing, eye, and colon function tests. Participants may sign separate consent forms for some tests. Participation will last indefinitely. Participants may be contacted once in a while by phone or mail. They may have follow-up visits.

Study Locations (2)

Maryland

  • National Institutes of Health Clinical Center - Bethesda
  • National Cancer Institute - Shady Grove - Rockville

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-04-25
Est. Completion 2035-01-31

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT04888936

The ClinicalTrials.gov registry entry for NCT04888936 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 293-participant average among 4 other Noonan Syndrome trials with a reported enrollment target (71% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Noonan Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT04888936 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04888936 about?

NCT04888936 is a clinical study titled "Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies". Background: RASopathies are a group of conditions caused by a genetic change. People with a RASopathy may have developmental issues, cognitive disability, poor growth, and birth defects. They may also have an increased risk for developing cancer. Researchers want to learn more. Objective: To learn...

What is the current status of trial NCT04888936?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2022-04-25. Estimated completion is 2035-01-31.

What conditions does trial NCT04888936 study?

This clinical trial studies the following conditions: Noonan Syndrome, Legius Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Capillary Arteriovenous Malformation Syndrome.

Who is sponsoring clinical trial NCT04888936?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04888936 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Noonan Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.